Competitive Advantages
- Reduces colorectal cancer cell growth and proliferation
- Does not harm healthy cells
- Applicable as anti-atypical PKC therapy
Summary
USF scientists have discovered that by inhibiting PKC-iota and PKC-zeta with certain drugs (ACPD, DNDA and ICA-1), a significant decrease in cancer cell proliferation is shown. Furthermore, an additional protein kinase inhibitor (zeta-Stat) demonstrated an increase in colorectal cancer cell death without compromising normal colon cell health. This novel method could improve treatments in colorectal cancer.
Percentage Inhibition of HT-29 Colorectal Cancer Cell Growth by the aPKC Inhibitor ACPD
Desired Partnerships
- License
- Sponsored Research
- Co-Development